This company analysis examines Forest’s current position and future outlook in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis, and an assessment of financial performance, with global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Understand how the impact of generic competition will shape Forest over the next six years
Benchmark Forest’s current and future strategic performance against its key rivals
Evaluate the success of Forest’s licensing focused business model
